Formation Bio Licenses Gusacitinib to Sanofi for Novel Indication Study
US-based AI-native pharma company Formation Bio announced the licensing of gusacitinib, an oral dual JAK/SYK...
Auto-immune
EMA Panel Recommends Bio-Thera’s Usymro for Autoimmune Diseases
The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA)...
Johnson & Johnson Submits sBLA to Expand Stelara Use for Pediatric Crohn’s Disease
US giant Johnson & Johnson (J&J, NYSE: JNJ) this week submitted a supplemental Biologics License...
GSK Launches ‘Linked by Lupus’ Initiative to Support Lupus Care with $1M Funding
UK-based pharmaceutical giant GlaxoSmithKline (GSK, NYSE: GSK) announced the launch of the Linked by Lupus:...
AbelZeta Pharma’s C-CAR168 Secures FDA RMAT Designation for Lupus Treatments
Sino-US biotech AbelZeta Pharma, Inc., based in Rockville, Maryland, and with operations in Shanghai, announced...
Bio-Thera Solutions’ BAT2206 Biosimilar of Stelara Gains FDA Approval
Guangzhou-based Bio-Thera Solutions Ltd. (SHA: 688177) announced that it has received Biologic License Application (BLA)...
Accropeutics’ AC-201 Shows Positive Phase II Results in Psoriasis Treatment
Suzhou-based Accropeutics Bioscience announced positive results from a Phase II study for its AC-201 in...
InnoCare Pharma Doses First Patient in Phase II/III Trial of TYK2 Inhibitor for Vitiligo
Chinese biotech InnoCare Pharma (HKG: 9969, SHA: 688428) has administered the first patient dose in...
Zelgen Biopharmaceuticals Submits New Indication Application for Jacktinib in Severe Alopecia Areata
China-based Suzhou Zelgen Biopharmaceuticals Co., Ltd (SHA: 688266) announced that it has submitted a new...
BRL Medicine Reports Positive Results for TyU19 in Refractory SLE Trial
Shanghai-based BRL Medicine Inc. announced positive results from an investigator-initiated trial (ITT) evaluating its allogeneic...
AbbVie’s Rinvoq Gains FDA Approval for Giant Cell Arteritis
US-based pharma giant AbbVie (NYSE: ABBV) announced regulatory approval from the US Food and Drug...
Kangpu Biopharmaceuticals Receives NMPA Approval for KPG-818 Phase IIb Study in SLE
China-based Kangpu Biopharmaceuticals, Ltd announced that it has received approval from the National Medical Products...
Genentech Collaborates with Repertoire Immune Medicines on Autoimmune Disease Therapies
Genentech, a subsidiary of Swiss pharmaceutical leader Roche (SWX: ROG, OTCMKTS: RHHBY) , announced a collaboration...
Akeso’s Ebdarokimab Receives NMPA Approval for Moderate to Severe Plaque Psoriasis
China’s Akeso Biopharma (HKG: 9926) announced that it has received marketing approval from the National...
Sanofi’s Dupixent Approved by FDA for Chronic Spontaneous Urticaria
France-based pharmaceutical major Sanofi (EPA: SAN, NASDAQ: SNY) has announced that the US Food and Drug...
Sanofi Licenses First-in-Class BsAbs from Earendil Labs for Autoimmune and IBD Treatment
French pharmaceutical giant Sanofi (EPA: SAN, NASDAQ: SNY) has entered into a licensing agreement with...
Boehringer Ingelheim Partners with Cue Biopharma to Advance CUE-501 for Autoimmune Diseases
Germany’s Boehringer Ingelheim (BI) has entered into a strategic agreement with US-based Cue Biopharma, Inc....
Hengrui Pharmaceuticals’ Vunakizumab Approved for Ankylosing Spondylitis
Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276) announced that it has received additional indication approval...
SinoMab BioScience’s SM17 Shows Promising Results in Phase Ib Atopic Dermatitis Study
Hong Kong-based biotech SinoMab BioScience Ltd (HKG: 3681) has announced positive results from the Phase...
Sunshine Guojian’s SSGJ-627 Gains NMPA Approval for Ulcerative Colitis Trial
China-based Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd, (SHA: 688336) a subsidiary of 3SBio Inc. (HKG:...